Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

OBJECTIVE: Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinyol, Roser, Montal, Robert, Bassaganyas, Laia, Sia, Daniela, Takayama, Tadatoshi, Chau, Gar-Yang, Mazzaferro, Vincenzo, Roayaie, Sasan, Lee, Han Chu, Kokudo, Norihiro, Zhang, Zhongyang, Torrecilla, Sara, Moeini, Agrin, Rodriguez-Carunchio, Leonardo, Gane, Edward, Verslype, Chris, Croitoru, Adina Emilia, Cillo, Umberto, de la Mata, Manuel, Lupo, Luigi, Strasser, Simone, Park, Joong-Won, Camps, Jordi, Solé, Manel, Thung, Swan N, Villanueva, Augusto, Pena, Carol, Meinhardt, Gerold, Bruix, Jordi, Llovet, Josep M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580745/
https://www.ncbi.nlm.nih.gov/pubmed/30108162
http://dx.doi.org/10.1136/gutjnl-2018-316408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580745/
https://www.ncbi.nlm.nih.gov/pubmed/30108162
http://dx.doi.org/10.1136/gutjnl-2018-316408

Ejemplares similares